Stockscreener 앱 받기
50.39
6.51%
3.08
시간 외 거래:
50.33
-0.06
-0.12%
Hemab Therapeutics Holdings Inc 주식(COAG)의 최신 뉴스
Hemab Therapeutics Holdings Ord Shs (Proposed) - TradingKey
Hemab Therapeutics Holdings, Inc. Revenue Breakdown – NASDAQ:COAG - TradingView
Ra Capital Nexus Fund Iv, L.p. Net Worth (2026) - GuruFocus
Mads Nikolaj Behrndt Eriksen Net Worth (2026) - GuruFocus
Biotech IPO gains crush numerous AI listings - PressReader
Biotech IPO gains crush AI listings with standout 55% return - The Edge Singapore
Ananthram Sreenivasa Murthy Net Worth (2026) - GuruFocus
SpaceX Stock Closes At Fresh Low After Seven Straight Days Of Losses - Yahoo Finance
Ai Den Mab Llc Net Worth (2026) - GuruFocus
The Robot Maker's Paradox - Yahoo Finance
Hemab Therapeutics (NASDAQ:COAG) Hits New 12-Month HighWhat's Next? - MarketBeat
Culpeo Minerals expands Chile landholding by 45% with new licences - Yahoo Finance
After Plunging 32.2% in 4 Weeks, Here's Why the Trend Might Reverse for D-WAVE QUANTUM (QBTS) - Yahoo Finance
Insight Global Opens New Seattle Hub to Support Next Phase of Growth Across the Pacific Northwest - Yahoo Finance
DiamondRock Hospitality Company (DRH) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
IREN stock jumps as AI cloud contract wins lift annual revenue target - Yahoo Finance
Why this venture capitalist is bullish on Anthropic's IPO — not OpenAI's - Yahoo Finance
Plug Power vs. FuelCell: Both Are Hot in 2026, but Only One Is Worth Buying Now - Yahoo Finance
QScreen AI Deepens US Institutional Pipeline as Screening Platform Adds Escalation-Based Review Capability - Yahoo Finance
Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Why Is Lucid (LCID) Stock Rocketing Higher Today - Yahoo Finance
Sellas Life (SLS) Climbs 12% Ahead of ‘Potentially Company-Defining’ Clinical Trial Result - Yahoo Finance
Hemab Therapeutics (NASDAQ:COAG) Shares Up 5.5%Here's What Happened - MarketBeat
WESTSHORE TERMINALS ANNOUNCES AGREEMENT RENEWAL WITH EVR OPERATIONS LIMITED - Yahoo Finance
Cracker Barrel (CBRL): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
Wall Street traders can soon pay for early looks at Truth Social posts - Yahoo Finance
Hemab Therapeutics Holdings, Inc. Common Stock (NASDAQ: COAG) Stock Price, News & Analysis - Kalkine
Is Perspective Therapeutics, Inc. (CATX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Hemab Therapeutics (NASDAQ:COAG) Trading Down 3.8%Should You Sell? - MarketBeat
Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN) - Yahoo Finance
FY2027 Earnings Estimate for COAG Issued By HC Wainwright - MarketBeat
Hemab Therapeutics' Sutacimig Continues to Support Durable Bleed Reduction, Wedbush Says - Moomoo
Why Is ASML Stock Jumping Over 5% Premarket Today? - Yahoo Finance
Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
Analysts Are Bullish on Top NA Stocks: HawkEye 360, Inc. (HAWK), SpaceX (SPCX) - The Globe and Mail
Hemab Therapeutics reports positive Phase 2 sutacimig data - grafa.com
Corning Earnings Preview: What to Expect - Yahoo Finance
Hemab Therapeutics: Strong HMB-002 Data Drive Higher Probability of Success and Lift Price Target from $36 to $46 with Buy Rating - TipRanks
Hemab Advances Bleeding Disorder Pipeline - Sahm
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress - The Manila Times
Hemab Therapeutics Presents Sustained Sutacimig Bleed Reduction Data and Preclinical Factor VII Deficiency Results at ISTH 2026 - Quiver Quantitative
Hemab GT study finds 72% of patients 40+ still bleed weekly - Stock Titan
H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $52 - Moomoo
COAG Maintained by Jefferies -- Price Target Raised to $47 - GuruFocus
Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $47 - Moomoo
Hemab Therapeutics' HMB-002 Well Suited for Type 1 Von Willebrand Disease, Wedbush Says - Moomoo
Hemab Therapeutics Hldgs Price Target Raised to $55.00/Share From $42.00 by Wedbush - Moomoo
Hemab Therapeutics (NASDAQ:COAG) Hits New 52-Week High on Analyst Upgrade - MarketBeat
COAG Maintains Rating by Wedbush -- Price Target Raised to $55 - GuruFocus
Hemab Therapeutics (COAG) Registration filing Summary - Quartr
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress - The Manila Times
Hemab Therapeutics Reports Positive HMB-002 Clinical Data in Von Willebrand Disease and Announces HMB-003 Program - Quiver Quantitative
New data hint at monthly injection option for VWD and heavy menstrual bleeding - Stock Titan
TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial - Yahoo Finance
Hemab Therapeutics Holdings(COAG) Stock Options Chain | Quotes & News - Moomoo
Price to book forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Polyrizon shares climb after NASARIX passes key biocompatibility testing (PLRZ) - Yahoo Finance
Wedbush Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $42 - Moomoo
Enterprise value to revenue forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Price to earnings forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Enterprise value to EBITDA forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Price to sales forward of Hemab Therapeutics Holdings, Inc. – NASDAQ:COAG - TradingView
Hemab Therapeutics Hldgs Price Target Maintained With a $40.00/Share by HC Wainwright & Co. - Moomoo
Hemab Therapeutics Holdings, Inc. Actuals & Estimates (NASDAQ:COAG) - TradingView
COAG Forecast — Price Target — Prediction for 2027 - TradingView
COAG Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress - The Manila Times
Hemab brings nine bleeding-disorder studies to ISTH 2026 in Paris - Stock Titan
1.97%
0.83%
자본화:
|
볼륨(24시간):